Adjunctive ZOL/IL-2 administrations during intermittent TB drugs treatment of MDR-TB-infected macaques could significantly enhance and sustain Vγ2Vδ2 T-effector subpopulations producing anti-TB cytokines from week 3 through week 21. This evidence concerns the gene IL2 and multidrug-resistant tuberculosis.